PremiumCompany AnnouncementsOrganogenesis Highlights Strategic Focus in Investor Presentation Organogenesis price target raised to $6 from $4 at Morgan Stanley Organogenesis Holdings Reports Strong Q4 Earnings Amid Challenges PremiumThe FlyOrganogenesis reports Q4 EPS 4c, consensus 2c Organogenesis files to sell 130K shares of common stock for holders Organogenesis assumed with an Equal Weight at Morgan Stanley PremiumThe FlyOrganogenesis reports Q3 EPS 9c, consensus (1c) Organogenesis reports Q3 EPS 9c, consensus (1c) Organogenesis sees FY24 revenue $455-$480M, consensus $456.15M